Galderma’s nemolizumab sets new standard in prurigo nodularis treatment with OLYMPIA 1 trial success
Galderma’s latest clinical trial has unveiled a significant breakthrough in treating prurigo nodularis, a chronic neuroimmune skin condition characterized by relentless itching and thickened skin ... Read More
Galderma launches phase 3 atopic dermatitis trial for nemolizumab
Galderma, a Nestle-owned Swiss pharma company, said that it has enrolled the first patients in a phase 3 clinical study evaluating nemolizumab for the treatment ... Read More